3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms
3
Non Small Cell Lung Carcinoma NSCLC
2
NSCLC
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Primary Breast Cancer
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Carcinoma
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
CP protocol
×
Clear all
NCT05201547
2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3
Active not recruiting
260 enrolled